Health
Novavax vaccine – Development, safety, and usage for 12-17 age group
The Novavax COVID-19 vaccine, known as NVX-CoV2373, has gained prominence for its usefulness and safety. Originally authorized for adults aged 18 and over, it recently received FDA approval for emergency use in adolescents between 12 and 17. This vaccine defends against COVID-19 with an innovative protein-based technology. An expansion of usage means a broader age group can benefit from the protection, bolstering efforts to curb the pandemic’s spread and keep younger populations safe. Additional approval from FDA The FDA granted the Novavax COVID-19 emergency use authorization for adolescents aged 12 to 17, endorsing it as a two-dose primary series. Additionally, the CDC director issued a decision memo permitting the use of the Novavax COVID vaccine as a primary series choice for this adolescent group. The availability of a vaccine option designed using conventional protein-based technology is seen as a benefit. Experts believe the vaccination rates may rise, especially since children are back to school and socializing. In related news, Novavax also worked on actively developing an updated version of its vaccine, tailored to target a specific variant of the virus and its offshoots. The company was looking forward to seeking authorization for this variant-targeting vaccine last year. Development and safety of the vaccine The development and safety of the Novavax COVID-19 vaccine for adolescents aged 12 to 17 have been carefully scrutinized and confirmed through comprehensive clinical trials.
Read More